Author:
Schlenk R F, ,Fröhling S,Hartmann F,Fischer J Th,Glasmacher A,del Valle F,Grimminger W,Götze K,Waterhouse C,Schoch R,Pralle H,Mergenthaler H G,Hensel M,Koller E,Kirchen H,Preiss J,Salwender H,Biedermann H G,Kremers S,Griesinger F,Benner A,Addamo B,Döhner K,Haas R,Döhner H
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference39 articles.
1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903.
2. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P et al. Granulocyte–macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671–1677.
3. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte–macrophage colony-stimulating factor in adult patients (>55–70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457–462.
4. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E et al. Use of recombinant granulocyte–macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952–2961.
5. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998; 91: 3607–3615.